Intermonte analyst Carlo Maritano has reiterated their bullish stance on 0RH2 stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Carlo Maritano has given his Buy rating due to a combination of factors relating to El.En.’s recent performance and outlook. Despite mixed quarterly margins, the company delivered stronger‑than‑expected revenues and robust cash generation, ended the year with a sizeable net cash position, and proposed a dividend slightly above prior projections, all of which underscore its solid financial footing.
At the same time, management expects revenues to grow in 2026 with an accompanying margin uplift, supported by healthy order intake across both Medical and Industrial divisions, and this guidance is seen as conservative given the company’s usual prudence. Maritano also highlights the increasing strategic weight of the Medical segment, the improved return on capital after exiting the Chinese cutting business, and potential upside from future capital allocation or portfolio decisions, which together justify a higher target price and a reaffirmed Buy recommendation.
According to TipRanks, Maritano is a 4-star analyst with an average return of 14.8% and a 71.43% success rate.
In another report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a €13.30 price target.